|
Artificial Neural Network for Prediction of Clinical Outcomes
Application
A machine learning model to predict the need for ventriculoperitoneal shunt after posterior fossa tumor resection.
Key Benefits
Highly accurate prediction of post-surgical complications.
Reducing healthcare costs by predicting prognoses and increasing efficiency of post-surgical treatment.
Market Summary
Neurosurgical procedures...
Published: 7/30/2024
Contributor(s): Kimberly Hoang, Ali Alawieh, David Bray
|
|
Combination Therapy to Overcome Resistance to Platinum-Based Chemotherapy
Application
MAST1 inhibitors to overcome resistance to platinum-based chemotherapy, exacerbated by dexamethasone co-administration.
Key Benefits
Co-administration of MAST1 inhibitor and MAST1-stabilizing protein inhibitor abrogates tumor resistance to cisplatin
MAST1 inhibitor, lestaurtinib, has previously reached phase III clinical trials and...
Published: 7/30/2024
Contributor(s): Sumin Kang, Jing Chen
|
|
Strategy to Identify miRNAs for Disease Diagnosis
Application
Method to measure precursor and mature miRNA specifically.
Key Benefits
Unique primers can specifically identify miRNAs and precursor miRNAs by standard qRT-PCR without the requirement for an additional detection probe.
Allows for amplification and quantification of both mature miRNA and precursor miRNAs.
Potential technology to evaluate...
Published: 9/26/2024
Contributor(s): Wenming Li
|
|
Hybrid Proton-Photon Inverse Optimization to Deliver Radiation Therapy
Application
Hybrid proton-photon inverse optimization method that synergizes proton and photon therapy with improved total optimization objectives for robust cancer treatment delivery.
Key Benefits
Improved planning target volume coverage and organ at risk sparing.
Reduced overall optimization values.
Less expensive treatment than proton therapy...
Published: 7/30/2024
Contributor(s): Hao Gao
|
|
Software for Reviewing Patients in Radiotherapy Chart Rounds
ApplicationSoftware program to help physicians streamline peer-review for radiotherapy patients during chart rounds.Key BenefitsIncreases efficiency and reduces time for reviewing patient chart records.Enables faster detection of errors and deviations.Provides standardized treatment for all patients.Improves quality and safety of cancer patient treatment.Market...
Published: 7/30/2024
Contributor(s): Eduard Schreibmann, Natia Esiashvili
|
|
Human Osteopontin Knock-in Mouse Line
ApplicationMouse lines expressing isoforms a, b, and c of the Human Osteopontin (OPN) protein for cancer research.Technical SummaryThe murine OPN is not subject to splicing and therefore does not express different isoforms. Human cancers express splice variants. Emory researchers developed these mouse models to express each isoform independently from...
Published: 9/26/2024
Contributor(s): Alicia Lyle
|
|
Small Molecule NOX Inhibitors of Human Melanoma Cell Proliferation
Application
Triphenylmethane small molecules inhibiting NADPH oxidase (NOX) for the anti-proliferation of melanoma tumor cells.
Key Benefits
Modifies molecular interactions with cellular proteins, reducing cell tumor growth.
Compounds are capable of inhibiting cell proliferation to a greater extent than current competing NOX inhibitors for melanoma...
Published: 9/26/2024
Contributor(s): Jack Arbiser
|
|
PI3Kα Inhibitors for the Treatment of Cancer
Application
Compounds that inhibit the kinase activity of phospoinostidie 3-kinase (PI3Kα) for the treatment of cancer.
Key Benefits
Potential therapeutic targeted to pathway without a clinically approved inhibitor.
Provides a useful pharmacological probe for research purposes.
Market Summary
In order to grow, cancer cells must have the...
Published: 11/20/2024
Contributor(s): Qi Shi, Thomas Kaiser, Dennis Liotta, James Snyder, Zackery Dentmon, John Diraddo
|
|
ARCaPE Cell Lines Expressing shRNAs of Human EPLIN
Application
Highly malignant and metastatic prostate cancer cell line.
Key Benefits
Prostate cancer cell line with reduced Epithelial Protein Lost In Neoplasm (EPLIN) expression.
Cell line exhibits morphology characteristics of malignant cell lines and increased chemoresistance, migration, and invasion.
Market Summary
Although the survival...
Published: 9/26/2024
Contributor(s): Daqing Wu, Shumin Zhang
|
|
Pre-B Acute Lymphoblastic Leukemia Cell Line EU-4
Application
Cancer cell line derived from a pediatric patient with early B-cell precursor (Pre-B) acute lymphoblastic leukemia with myeloid phenotype.
Key Benefits
Does not express p53 and expresses wild-type MDM2.
Expresses wild-type Bax, over-expresses Bcl-xl, and does not express Bcl-2.
Can be used as a tool for gene transfection assays in...
Published: 11/20/2024
Contributor(s): Muxiang Zhou, Lu Bing Gu
|
